Lantheus (LNTH) investor relations material

Executive summary

• Entered into a Merger Agreement with Curium US Holdings LLC, with the company to become a wholly owned subsidiary upon completion of the merger, expected in the first half of 2027.

• Regulatory review ongoing; pre-merger notification was withdrawn and refiled to allow the FTC additional review time, starting a new 30-day waiting period expiring October 21, 2026.

• Forward-looking statements highlight expectations for successful merger completion, continued commercialization of marketed products, and advancement of late-stage pipeline.

• Risks include regulatory approval timing, potential competing offers, integration challenges, and market adoption of new products.

Voting matters and shareholder proposals

• Stockholder approval of the Merger Agreement is required for the transaction to proceed.

• Proxy materials have been filed and stockholders are urged to review them for important information regarding the proposed acquisition.

Board of directors and corporate governance

• Directors, executive officers, and employees may participate in the solicitation of proxies for the merger.

• Information on directors and executive officers, including changes in securities holdings, is available in the proxy statement and related SEC filings.